APA

Parra H. S., Tixi L., Latteri F., Bretti S., Alloisio M., Gravina A., Lionetto R., Bruzzi P., Dani C., Rosso R., Cosso M., Balzarini L., Santoro A. & Ardizzoni A. (20010830). Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). : Cancer.

Chicago

Parra H S, Tixi L, Latteri F, Bretti S, Alloisio M, Gravina A, Lionetto R, Bruzzi P, Dani C, Rosso R, Cosso M, Balzarini L, Santoro A and Ardizzoni A. 20010830. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). : Cancer.

Harvard

Parra H. S., Tixi L., Latteri F., Bretti S., Alloisio M., Gravina A., Lionetto R., Bruzzi P., Dani C., Rosso R., Cosso M., Balzarini L., Santoro A. and Ardizzoni A. (20010830). Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). : Cancer.

MLA

Parra H S, Tixi L, Latteri F, Bretti S, Alloisio M, Gravina A, Lionetto R, Bruzzi P, Dani C, Rosso R, Cosso M, Balzarini L, Santoro A and Ardizzoni A. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). : Cancer. 20010830.